Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hippuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.66 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | PTPRC | P08575 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hippuric Acid SCHEMBL7796688 | 1.00 | KDM4E (0.66) | KDM4EMAPTHIF1ASLC22A6SLC22A8 | |
| Hippuric Acid SCHEMBL428479 | 0.98 | GAA (0.68) | KDM4EMAPTHIF1ASLC22A6SLC22A8 | |
| SCHEMBL22030672 | 0.98 | GAA (0.68) | KDM4EMAPTHIF1ASLC22A6SLC22A8 | |
| Hippuric Acid SCHEMBL7486 | 0.98 | GAA (0.68) | KDM4EMAPTHIF1ASLC22A6SLC22A8 | |
| Hippuric Acid SCHEMBL11656206 | 0.96 | MAPT (0.66) | KDM4EMAPTHIF1ASLC22A6SLC22A8 | |
| Hippuric Acid SCHEMBL21569381 | 0.96 | MAPT (0.66) | KDM4EMAPTHIF1ASLC22A6SLC22A8 | |
| Hippuric Acid SCHEMBL8165809 | 0.96 | MAPT (0.66) | KDM4EMAPTHIF1ASLC22A6SLC22A8 | |
| Hippuric Acid SCHEMBL3448563 | 0.96 | MAPT (0.66) | KDM4EMAPTHIF1ASLC22A6SLC22A8 | |
| Hippuric Acid SCHEMBL11709120 | 0.96 | MAPT (0.66) | KDM4EMAPTHIF1ASLC22A6SLC22A8 | |
| Hippuric Acid SCHEMBL15416338 | 0.96 | MAPT (0.66) | KDM4EMAPTHIF1ASLC22A6SLC22A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766464-B2 | Method for gut mucosa preparation to enhance microbial engraftment | MILIS ANTONY (AU) | 2023-09-26 | — | — | US | claimed |
| US-20220233437-A1 | DEVICES, COMPOSITIONS AND METHODS FOR COLONIC MICROBIOME ENGRAFTMENT | BORODY THOMAS J (AU) | 2022-07-28 | — | — | US | claimed |
| US-20220226399-A1 | METHOD FOR GUT MUCOSA PREPARATION TO ENHANCE MICROBIAL ENGRAFTMENT | MILIS ANTONY (AU) | 2022-07-21 | — | — | US | claimed |
| EP-3996727-A1 | METHOD FOR GUT MUCOSA PREPARATION TO ENHANCE MICROBIAL ENGRAFTMENT | Milis, Antony (AU) | 2022-05-18 | — | — | EP | claimed |
| CN-114364388-A | Preparation method of intestinal mucosa for enhancing microbial implantation | 安东尼·米利斯 | 2022-04-15 | — | — | CN | claimed |
| EP-3976030-A1 | DEVICES, COMPOSITIONS AND METHODS FOR COLONIC MICROBIOME ENGRAFTMENT | Borody, Thomas Julius (AU) | 2022-04-06 | — | — | EP | claimed |
| WO-2021003535-A1 | METHOD FOR GUT MUCOSA PREPARATION TO ENHANCE MICROBIAL ENGRAFTMENT | MILIS ANTONY (AU) | 2021-01-14 | — | — | WO | claimed |
| WO-2020237323-A1 | DEVICES, COMPOSITIONS AND METHODS FOR COLONIC MICROBIOME ENGRAFTMENT | BORODY THOMAS J (AU) | 2020-12-03 | — | — | WO | claimed |
| US-7670967-B2 | Dispersible alcohol/cleaning wipes via topical or wet-end application of acrylamide or vinylamide/amine polymers | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2010-03-02 | — | — | US | claimed |
| US-20090252861-A1 | NEW ANTIMICROBIAL MATERIAL | CENTRE DES TECHNOLOGIES TEXTILES (CA) | 2009-10-08 | — | — | US | claimed |
| US-20060141015-A1 | Antimicrobial material | CENTRE DES TECHNOLOGIES TEXTILES (CA) | 2006-06-29 | — | — | US | claimed |
| US-20060003649-A1 | Dispersible alcohol/cleaning wipes via topical or wet-end application of acrylamide or vinylamide/amine polymers | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2006-01-05 | — | — | US | claimed |
| US-20030021841-A1 | Pharmaceutical composition | MATHARU AMOL SINGH (US) | 2003-01-30 | — | — | US | claimed |
| WO-2003004009-A1 | PHARMACEUTICAL COMPOSITION | GENEVA PHARMACEUTICALS, INC. (US) | 2003-01-16 | — | — | WO | claimed |
| US-4952402-A | EDIBLE TASTE-MASKED DRUGS; MICROMATRIX ACTIVE MATERIAL COATED WITH NONTOXIC POLYMER; LIQUIDS; TABLETS | ELAN CORPORATION, P.L.C. (IE) | 1990-08-28 | — | — | US | claimed |
| US-4369172-A | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose | FOREST LABORATORIES INC. (US) | 1983-01-18 | — | — | US | claimed |
| US-12605336-B2 | Fusogenic liposome-coated porous silicon nanoparticles | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-21 | — | — | US | disclosed |
| US-12178912-B2 | Twin-screw dry granulation for producing solid formulations | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-12-31 | — | — | US | disclosed |
| US-4940588-A | Pharmaceutical, polymer microparticle | ELAN CORPORATION (IE) | 1990-07-10 | — | — | US | disclosed |
| US-4369172-A | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose | FOREST LABORATORIES INC. (US) | 1983-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605336-B2 | Fusogenic liposome-coated porous silicon nanoparticles | NSF, FUS, STIM1 | KDM4E 2681/4885MAPT 1246/4885HIF1A 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.